Trial Profile

A Phase 3 Open-label Safety Trial of PH94B Nasal Spray in the Acute Treatment of Anxiety in Adult Subjects With Social Anxiety Disorder (SAD)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 09 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fasedienol (Primary)
Indications Anxiety disorders; Social phobia
Focus Adverse reactions; Registrational
Acronyms PALISADE Long-term Safety Study
Sponsors VistaGen Therapeutics

Most Recent Events

07 Nov 2023 According to a Vistagen media release, data from this trial will be presented at the 2023 Neuroscience Education Institute (NEI) Congress.
01 Jun 2023 According to a VistaGen Therapeutics media release, data from this study were presented at American Society for Clinical Psychopharmacology (ASCP) Annual Meeting.
01 Jun 2023 Results presented in a VistaGen Therapeutics media release Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com